Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium-Reference-Cited by-同舟云学术

Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

Published:2020-10-30 Issue:10 Volume:17 Page:e1003348
ISSN:1549-1676
Container-title:PLOS Medicine
language:en
Short-container-title:PLoS Med

Author:

Hässler Signe^ORCID,Bachelet Delphine^ORCID,Duhaze Julianne^ORCID,Szely Natacha,Gleizes Aude,Hacein-Bey Abina Salima,Aktas Orhan^ORCID,Auer Michael^ORCID,Avouac Jerôme^ORCID,Birchler Mary,Bouhnik Yoram,Brocq Olivier,Buck-Martin Dorothea,Cadiot Guillaume,Carbonnel Franck,Chowers Yehuda,Comabella Manuel^ORCID,Derfuss Tobias,De Vries Niek^ORCID,Donnellan Naoimh,Doukani Abiba,Guger Michael^ORCID,Hartung Hans-Peter,Kubala Havrdova Eva^ORCID,Hemmer Bernhard,Huizinga Tom,Ingenhoven Kathleen,Hyldgaard-Jensen Poul Erik,Jury Elizabeth C.^ORCID,Khalil Michael^ORCID,Kieseier Bernd,Laurén Anna,Lindberg Raija^ORCID,Loercher Amy^ORCID,Maggi Enrico,Manson Jessica^ORCID,Mauri Claudia,Mohand Oumoussa Badreddine,Montalban Xavier,Nachury Maria^ORCID,Nytrova Petra,Richez Christophe,Ryner Malin,Sellebjerg Finn,Sievers Claudia,Sikkema Dan,Soubrier Martin^ORCID,Tourdot Sophie,Trang Caroline^ORCID,Vultaggio Alessandra,Warnke Clemens^ORCID,Spindeldreher Sebastian^ORCID,Dönnes Pierre^ORCID,Hickling Timothy P.,Hincelin Mery Agnès,Allez Matthieu^ORCID,Deisenhammer Florian^ORCID,Fogdell-Hahn Anna^ORCID,Mariette Xavier^ORCID,Pallardy Marc,Broët Philippe^ORCID,

Funder

Innovative Medicines Initiative

European Federation of Pharmaceutical Industries and Associations

Publisher

Public Library of Science (PLoS)

Subject

General Medicine

Reference59 articles.

1. Immunogenicity of Biopharmaceuticals

2. Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations.;G Shankar;AAPS J,2014

3. Assessing the Immunogenicity of Biopharmaceuticals.;C Pineda;BioDrugs,2016

4. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium: Immunogenicity of biopharmaceuticals: ABIRISK recommendations;B Rup;Clin Exp Immunol,2015

5. ABIRISK Consortium. ABIRISK: Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk [Internet]. 2018 [cited 2020 Jan 1]. Available from: https://www.imi.europa.eu/projects-results/project-factsheets/abiriskref:end

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity;Clinical Immunology;2024-10

2. Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis;Frontiers in Immunology;2024-05-15

3. Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis;Biomolecules;2024-05-03

4. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

5. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis;Gastroenterología y Hepatología (English Edition);2024-05